retatrutide expected release date UK 2026: Slinic Retatrutide, Eli Lilly's new experimental

Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S

Cienfuegos S, et al

Pharmacogenomics J 2003

Less common but important GLP-1 agonist side effects include increased heart rate in some patients, potential increased risk of gallbladder disease with rapid weight loss, and theoretical concerns about pancreatitis and thyroid C-cell tumors (though these risks remain controversial and may not be clinically significant)

Additionally, TB-500 exhibits anti-inflammatory properties that may further contribute to its therapeutic effects [4]

10.3389/fphys.2019.00428 65